Detailed price information for Serina Therapeutics Inc (SER-A) from The Globe and Mail including charting and trades.

Nasus Pharma (NYSE:NSRX) released top-line Phase 2 data for its investigational intranasal powder, NS002, that does more than just offer a needle-free alternative. The data suggests that Nasus has ...

By John Vandermosten, CFA NYSE: NSRX Nasus (NYSE: NSRX) reported topline results from its pharmacokinetic (PK) and pharmacodynamic (PD) Phase II study of NS002 on March 16th, 2026. This follows ...

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% ...

WARNING: the level scaling has changed as of the jade shadows update in june 2024. This video remains live as a historical ...

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based ...

Crimson Desert features skills that let you slingshot yourself into the air, create a shield of spiritual energy, and just ...

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, March 10, ...

It's the third day of the Midnight Season 1 Race to World First and the rush through the Voidspire raid has slowed down, but ...

Looking to quickly complete the Fortnite Chapter 7 Season 1 Battle Pass before the seasonal reset? Check out our guide for ...

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the ...